Startups
Evidera is a business within Pharmaceutical Product Development, LLC, (PPD) a leading global contract research organization (CRO), and is the preeminent provider of evidence-based solutions to demonstrate the real-world effectiveness, safety, and value of biopharmaceutical and biotechnology products from early development through loss of exclusivity. We provide integrated scientific expertise and global operational capabilities to help you generate the evidence needed to optimize the market access and commercial potential of your products.
Evidera was acquired by PPD in 2016 and originally created in 2013 as an independent company under the ownership of Symphony Technology Group following the acquisition of long-standing health economics, outcomes research, market access, epidemiology, and data analytics practices from United BioSource Corporation (UBC). Evidera has over 30 years of leadership and experience and its legacy brands include MEDTAP, Caro Research, Abt Bio-Pharmaceutical Solutions, MetaWorks, Total Healthcare Group, and Archimedes.
Evidera was acquired by PPD in 2016 and originally created in 2013 as an independent company under the ownership of Symphony Technology Group following the acquisition of long-standing health economics, outcomes research, market access, epidemiology, and data analytics practices from United BioSource Corporation (UBC). Evidera has over 30 years of leadership and experience and its legacy brands include MEDTAP, Caro Research, Abt Bio-Pharmaceutical Solutions, MetaWorks, Total Healthcare Group, and Archimedes.
Overview
Location
United States, Maryland, Bethesda
Employees
501-1000
Founded date
2013
Mentions in press and media 20
| Date | Title | Description |
| Sign up to see | Sign up to see | Sign up to see |
| Nov 13, 2024 | Navigating the Inflation Reduction Act: Reassessing Evidence and Value Needs for Price Negotiations, Upcoming Webinar Hosted by Xtalks | www.evidera.com In this free webinar, a diverse panel of experts, including those specializing in market access, real-world evidence (RWE), evidence synthesis and payer perspectives will provide an in-depth look at the implications of the I... |
| Aug 17, 2024 | The Weight of Change: Understanding Sarcopenia in the Age of GLP-1 Therapies | In the realm of weight loss, the conversation is shifting. Once dominated by the scale, it now embraces the complexity of body composition. At the forefront of this evolution are GLP-1 receptor agonists, a class of medications that promise ... |
| Aug 16, 2024 | Beyond Numbers: The Value of In-Trial Interview Data for Regulatory and Health Technology Assessment (HTA) Decision-Making, Upcoming Webinar Hosted by Xtalks | www.evidera.com In this free webinar, discover the value of in-trial interview data in drug development. Attendees will learn how in-trial qualitative data are used by regulators and health technology assessment (HTA) bodies. Attendees can ... |
| May 22, 2024 | Registries: Supercharging Real-World Evidence for Drug Development and Approval, Upcoming Webinar Hosted by Xtalks | www.evidera.com In this free webinar, learn about the various type of registries and what differentiates them. Attendees will be able to identify the right type of data for their needs and see what types of questions can be answered with re... |
| Jun 13, 2023 | Implementation Science: Driving Successful Uptake of Medicines and Medical Innovations in Healthcare Delivery, Upcoming Webinar Hosted by Xtalks | Register for this webinar to learn more about how implementation science methods and research approaches can help provide the evidence needed to support the uptake, adoption and sustained use of new medicinal products and medical care innov... |
| Mar 20, 2023 | Eisai publishes societal value of lecanemab using phase 3 Clarity AD data in peer-reviewed Neurology and Therapy journal | Eisai publishes societal value of lecanemab using phase 3 Clarity AD data in peer-reviewed Neurology and Therapy journal Mon, Mar 20, 2023 00:30 CET Report this content Stockholm, March 20, 2023 – BioArctic AB’s (publ) (Nasdaq Stockholm: BI... |
| Apr 27, 2022 | Modeling published in Neurology and Therapy suggests that lecanemab could delay progression to Alzheimer's dementia by several years | Modeling published in Neurology and Therapy suggests that lecanemab could delay progression to Alzheimer's dementia by several years Wed, Apr 27, 2022 08:00 CET Report this content Stockholm, April 27, 2022 – BioArctic AB’s (publ) (Nasdaq S... |
| Apr 12, 2022 | Mind & Machine: What’s next for neural interfaces? Matt Vallin takes a deep-dive into the future of wearable therapies and brain-controlled computing | We have so much to learn about the brain. Identifying which neurons or groups of neurons correspond to a specific action, thought, process or disease pathway is incredibly difficult. Every week we come across fascinating developments. Just ... |
| Feb 17, 2022 | How Digital Therapeutics Platforms Are Revolutionizing Healthcare Delivery | Co-Founder of Rocket VR Health. |
Show more
Reviews 0
FAQ about Evidera
When was Evidera founded?
Evidera was founded in 2013.
What has the press written about Evidera?
Parsers VC has collected 20 articles mentioning Evidera, among them “Navigating the Inflation Reduction Act: Reassessing Evidence and Value Needs for Price Negotiations, Upcoming Webinar Hosted by Xtalks” (Nov 13, 2024) and “The Weight of Change: Understanding Sarcopenia in the Age of GLP-1 Therapies” (Aug 17, 2024).
Is Evidera still active?
Yes, Evidera is active; its latest activity on Parsers VC dates from Nov 13, 2024.